RESUMEN
BACKGROUND: Endocrinopathies are common in patients with ß-thalassemia major despite parenteral iron chelation therapy with deferoxamine. Prevalence of abnormal glucose metabolism in previous studies was controversial. The aim of this study was to discuss the prevalence of abnormal glucose metabolism in ß-thalassemia major based on a meta-analysis. METHODS: PubMed, ScienceDirect, Springerlink, Ovid, Web of Science, MEDLINE, Wanfang database, and Chinese National Knowledge Internet were searched for relevant articles. Two authors selected the articles according to the inclusion criteria and then extracted the data. The prevalence of diabetes mellitus (DM) in ß-thalassemia major was defined as the primary outcome. The prevalence with the 95% confidence interval (95%CI) was used to evaluate the proportion of abnormal glucose metabolism and other endocrine disorders in patients with ß-thalassemia major. Subgroup analyses were applied to explore the prevalence in different regions. Sensitivity analysis and publication bias assessment were also conducted. RESULTS: A total of 44 studies with 16605 cases were included in this analysis. Diabetes mellitus was present in 6.54% (95% CI: 5.30%-7.78%). The fixed subgroup study revealed that the region with the highest prevalence was the Middle East (prevalence= 7.90%, 95% CI: 5.75%-10.05%). The accumulated meta-analysis revealed that the prevalence of DM in ß-thalassemia major was relatively steady in each year. The prevalence of impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and other endocrine disorders in ß-thalassemia major was 17.21% (95% CI: 8.43%-26.00%), 12.46% (95% CI: 5.98%-18.94%), and 43.92% (95% CI: 37.94%-49.89%), respectively. Sensitivity analysis showed that the pooled results were robust; publication bias assessment revealed that there was no significant evidence that the pooled results were influenced by publication bias. CONCLUSION: High prevalence of endocrine disorders involving abnormal glucose metabolism was detected in ß-thalassemia major. Treatment and prevention measurements may be necessary to prevent growth and endocrine problems.
Asunto(s)
Diabetes Mellitus/epidemiología , Enfermedades del Sistema Endocrino/epidemiología , Glucosa/metabolismo , Talasemia beta/epidemiología , Terapia por Quelación , Deferoxamina/uso terapéutico , Diabetes Mellitus/metabolismo , Diabetes Mellitus/patología , Enfermedades del Sistema Endocrino/complicaciones , Enfermedades del Sistema Endocrino/metabolismo , Enfermedades del Sistema Endocrino/patología , Intolerancia a la Glucosa , Humanos , Quelantes del Hierro/uso terapéutico , Medio Oriente/epidemiología , Talasemia beta/complicaciones , Talasemia beta/metabolismo , Talasemia beta/patologíaRESUMEN
Introduction of MRI techniques for identifying and monitoring tissue iron overload and the current understanding of iron homeostasis in transfusion-dependent (TDT) and non-transfusion-dependent thalassemia have allowed for a more robust administration of iron chelation therapies. The development of safe and efficient oral iron chelators and the insights gained from large-scale prospective studies using these agents have improved iron overload management. A significant reduction in iron toxicity-induced morbidity and mortality and improvements in quality of life were observed in TDT. The appropriate management of tissue-specific iron loading in TDT has been portrayed using evidence-based data obtained from investigational studies.
Asunto(s)
Quelantes del Hierro/uso terapéutico , Sobrecarga de Hierro/tratamiento farmacológico , Sobrecarga de Hierro/etiología , Talasemia/complicaciones , Biomarcadores , Transfusión Sanguínea , Terapia por Quelación , Enfermedades del Sistema Endocrino/tratamiento farmacológico , Enfermedades del Sistema Endocrino/etiología , Enfermedades del Sistema Endocrino/metabolismo , Enfermedades del Sistema Endocrino/prevención & control , Humanos , Hierro/metabolismo , Sobrecarga de Hierro/diagnóstico , Sobrecarga de Hierro/metabolismo , Hígado/diagnóstico por imagen , Hígado/metabolismo , Hígado/patología , Imagen por Resonancia Magnética , Talasemia/metabolismo , Talasemia/terapiaRESUMEN
We report the first evaluation of bone quality in 70 thalassemia intermedia (TI) patients (37 males, 33 females, age 41 ± 12 years). Thirty-three patients (47%) had been transfused, 34 (49%) had been splenectomized, 39 (56%) were on iron chelation therapy, and 11 (16%) were on hydroxyurea. Mean hemoglobin was 9.2 ± 1.5 g/dl, median ferritin 537 ng/dl (range 14-4893), and mean liver iron concentration 7.6 ± 6.4 mg Fe/g dw. Fifteen patients (21%) had endocrinopathies, and 29 (41%) had vitamin D deficiency. Bone quantity (bone mineral density, BMD) and bone quality (trabecular bone score, TBS) were evaluated by densitometry. In 53/70 patients (76%), osteopathy was found (osteoporosis in 26/53, osteopenia in 27/53). BMD values were higher in the never-transfused patients and in the not-chelated group. A highly significant correlation was found between splenectomy and BMD at all the sites, with lower values in the splenectomized patients. TBS values were significantly lower in TI patients than in 65 non-thalassemic controls (1.22 vs 1.36, p < 0.01), mainly in those splenectomized and in the transfused and chelated groups (p < 0.01). TBS did not correlate with liver iron concentration values. Our data disclose the major role of non-invasive bone quality evaluation in TI patients, especially those with the worst health state, to obtain a comprehensive assessment of fracture risk. Splenectomy seems to play a major part in bone complications.
Asunto(s)
Densidad Ósea , Huesos/metabolismo , Talasemia beta/metabolismo , Absorciometría de Fotón , Adulto , Enfermedades Óseas Metabólicas/complicaciones , Enfermedades Óseas Metabólicas/metabolismo , Enfermedades del Sistema Endocrino/complicaciones , Enfermedades del Sistema Endocrino/metabolismo , Femenino , Humanos , Sobrecarga de Hierro/complicaciones , Sobrecarga de Hierro/metabolismo , Masculino , Persona de Mediana Edad , Osteoporosis/complicaciones , Osteoporosis/metabolismo , Talasemia beta/complicacionesRESUMEN
CONTEXT: There is no doubt that vitamin D must be activated to the hormonal form 1,25-dihydroxyvitamin D to achieve full biological activity or that many tissues participate in this activation process-be it endocrine or autocrine. We believe that not only is 25-hydroxyvitamin D important to tissue delivery for this activation process, but also that intact vitamin D has a pivotal role in this process. OBJECTIVE: In this review, evidence on the vitamin D endocrine/autocrine system is presented and discussed in relation to vitamin D-binding protein affinity, circulating half-lives, and enzymatic transformations of vitamin D metabolites, and how these affect biological action in any given tissue. CONCLUSIONS: Circulating vitamin D, the parent compound, likely plays an important physiological role with respect to the vitamin D endocrine/autocrine system, as a substrate in many tissues, not originally thought to be important. Based on emerging data from the laboratory, clinical trials, and data on circulating 25-hydroxyvitamin D amassed during many decades, it is likely that for the optimal functioning of these systems, significant vitamin D should be available on a daily basis to ensure stable circulating concentrations, implying that variation in vitamin D dosing schedules could have profound effects on the outcomes of clinical trials because of the short circulating half-life of intact vitamin D.
Asunto(s)
Comunicación Autocrina , Sistema Endocrino/metabolismo , Vitamina D/metabolismo , 25-Hidroxivitamina D 2/sangre , 25-Hidroxivitamina D 2/metabolismo , Animales , Calcifediol/sangre , Calcifediol/metabolismo , Calcitriol/sangre , Calcitriol/metabolismo , Suplementos Dietéticos , Enfermedades del Sistema Endocrino/etiología , Enfermedades del Sistema Endocrino/metabolismo , Enfermedades del Sistema Endocrino/prevención & control , Ergocalciferoles/sangre , Ergocalciferoles/metabolismo , Humanos , Vitamina D/administración & dosificación , Vitamina D/sangre , Vitamina D/uso terapéutico , Deficiencia de Vitamina D/dietoterapia , Deficiencia de Vitamina D/metabolismo , Deficiencia de Vitamina D/fisiopatologíaRESUMEN
AIM: To evaluate the efficiency of combined central and local physiotherapeutic procedures in correcting neuroendocrine and menstrual disorders in pubertal girls (PG) with obesity. SUBJECTS AND METHODS: Eighty-seven PGs, including 67 with different levels of obesity and 20 healthy non-obese girls, were examined. The hormonal profile, lipidogram, and fasting insulin and glucose levels were studied. Body mass index (BMI) and waist and hip circumferences were estimated. The functional state of the central nervous system was studied by electroencephalography. The parameters of the autonomic nervous system were estimated by cardiointervalography. The PGs with obesity were divided into 2 groups: a study group (SG) (n = 40) and a control group (CG) (n = 27). The healthy PGs (n = 20) formed a comparison group. The SG patients received bitemporal transcranial magnetic therapy in combination with frontomastoid transcranial electrostimulation, as well as myoelectrostimulation of the anterior abdominal wall, by transferring the area of stimulation from right to left hypochondrium. A course consisted of 10-15 daily sessions. CG had placebo physioprocedures (with disconnected electrodes). RESULTS: After 6-month treatment, SG and CG showed average reductions in BMI by 5.9 and 2.5 kg/m2, respectively. Lipidograms normalized in 70%; menstrual cycles were restored in 25 of 30 patients with impaired cycles in SG and in 1 of 22 in CG. Hormonal profiles were significantly improved in 62.5% of the patients in SG and unchanged in CG. CONCLUSION: The high efficiency of combined (central and local) physiotherapeutic procedures is likely to be dueto the normalization of pituitary-ovarian relationships and enables one to recommend the proposed procedure in a rehabilitation program for PGs with obesity and reproductive system disorders.
Asunto(s)
Terapia por Estimulación Eléctrica , Enfermedades del Sistema Endocrino/terapia , Obesidad/terapia , Estimulación Magnética Transcraneal , Pared Abdominal/fisiología , Adolescente , Índice de Masa Corporal , Niño , Terapia Combinada/instrumentación , Terapia Combinada/métodos , Electroencefalografía , Enfermedades del Sistema Endocrino/metabolismo , Enfermedades del Sistema Endocrino/fisiopatología , Femenino , Humanos , Ciclo Menstrual/metabolismo , Obesidad/metabolismo , Obesidad/fisiopatología , Placebos , Lóbulo Temporal/fisiología , Resultado del TratamientoRESUMEN
OBJECTIVES: Bipolar disorder (BD) is intricately associated with chronic clinical conditions. Medical comorbidity is not only more prevalent in mood disorders, but is associated with increased costs, cognitive impairment and, ultimately, premature mortality. Oxidative stress and inflammation may mediate part of this association. To further investigate the association between medical comorbidity status and clinical improvement with adjuvant N acetyl cysteine (NAC) in the context of a placebo-controlled trial. METHODS: Placebo-controlled randomized clinical trial assessing the effect of NAC over 24 weeks. Symptomatic and functional outcomes were collected over the study period. Medical comorbidities were self-reported, and we took special interest in cardiovascular and endocrine conditions. We evaluated change from baseline to endpoint and the interaction between change and reported medical comorbidities. RESULTS: Fifty-one percent of patients reported have a cardiovascular or endocrine comorbidity. Although not found for depressive symptoms or quality of life, a significant interaction between medical comorbidity and change scores was consistently found for all functional outcomes. This indicated an advantage of NAC over placebo in those with a clinical comorbidity. CONCLUSION: Systemic illness moderated only the effect of NAC on functioning, not on depression. Demonstrating an improvement in functional outcomes with an agent that modulates redox and inflammatory pathways, this study lends empirical support to the idea that medical and psychiatric comorbidity are additive in contributing to allostatic states. One intriguing possibility is that comorbid clinical illness could be a marker for more severe oxidative stress states--and thus guide antioxidant use--in BD.
Asunto(s)
Acetilcisteína/uso terapéutico , Trastorno Bipolar/tratamiento farmacológico , Trastorno Bipolar/epidemiología , Depuradores de Radicales Libres/uso terapéutico , Acetilcisteína/metabolismo , Acetilcisteína/farmacología , Adulto , Trastorno Bipolar/metabolismo , Enfermedades Cardiovasculares/tratamiento farmacológico , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/metabolismo , Método Doble Ciego , Enfermedades del Sistema Endocrino/tratamiento farmacológico , Enfermedades del Sistema Endocrino/epidemiología , Enfermedades del Sistema Endocrino/metabolismo , Femenino , Depuradores de Radicales Libres/metabolismo , Depuradores de Radicales Libres/farmacología , Humanos , Inflamación/tratamiento farmacológico , Inflamación/epidemiología , Inflamación/metabolismo , Masculino , Persona de Mediana Edad , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/fisiologíaRESUMEN
Gonadotropin-releasing hormone (GnRH) receptor agonists have wide clinical applications including the treatment of prostate cancer and endocrine disorders. However, such agonists are characterized by poor pharmacokinetic properties, often requiring repeated administration or special formulations. Therefore, the development of novel peptide analogs with enhanced in vivo stability could potentially provide therapeutic alternatives. The pharmacological evaluation of a bioactive peptide [Des-Gly¹°,Tyr5(OMe),D-Leu6,Aze-NHEt9]GnRH, analog 1, is presented herein and compared with leuprolide. Peptide stability was evaluated using mouse kidney membrane preparations, followed by a liquid chromatography-tandem mass spectrometry-based approach that afforded identification and quantification of its major metabolites. The analog was significantly more stable in vitro in comparison with leuprolide. In vitro and in vivo stability results correlated well, encouraging us to develop a clinically relevant pharmacokinetic mouse model, which facilitated efficacy measurements using testosterone as a biomarker. Analog 1, an agonist of the GnRH receptor with a binding affinity in the nanomolar range, caused testosterone release in mice that was acutely dose-dependent, an effect blocked by the GnRH receptor antagonist cetrorelix. Repeated dosing studies in mice demonstrated that analog 1 was well tolerated and had potency similar to that of leuprolide, based on plasma and testis testosterone reduction and histopathological findings. Analog 1 also shared with leuprolide similar significant antiproliferative activity on androgen-dependent prostate cancer (LNCaP) cells. On the basis of pharmacokinetic advantages, we expect that analog 1 or analogs based on this new design will be therapeutically advantageous for the treatment of cancer and endocrine disorders.
Asunto(s)
Enfermedades del Sistema Endocrino/tratamiento farmacológico , Hormona Liberadora de Gonadotropina/análogos & derivados , Hormona Liberadora de Gonadotropina/uso terapéutico , Neoplasias de la Próstata/tratamiento farmacológico , Animales , Antineoplásicos Hormonales/química , Antineoplásicos Hormonales/metabolismo , Antineoplásicos Hormonales/uso terapéutico , Células CHO , Línea Celular , Cricetinae , Cricetulus , Evaluación Preclínica de Medicamentos/métodos , Enfermedades del Sistema Endocrino/metabolismo , Hormona Liberadora de Gonadotropina/metabolismo , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Neoplasias de la Próstata/metabolismo , Receptores LHRH/metabolismo , Resultado del TratamientoRESUMEN
A 30-year-old normocalcemic man with hypopituitarism, hypogonadism, diabetes mellitus, and secondary hemochromatosis due to multiple blood transfusions was admitted because of adrenal crisis. After intravenous administration of saline and cortisol, the corrected serum level of calcium decreased to 7.3 mg/dl. This osteoporotic patient had been prescribed alendronate for radial bone fracture. Since the increase in intact PTH (68 pg/ml) was impaired compared to that seen in hypocalcemic patients with secondary hyperparathyroidism, we presume that the patient has had latent hypoparathyroidism, which was unmasked by the administration of glucocorticoid and bisphosphonate. With a supplemented dose of 1alpha-OHD3, the patient has been eucalcemic.
Asunto(s)
Alendronato/uso terapéutico , Enfermedades del Sistema Endocrino/metabolismo , Glucocorticoides/uso terapéutico , Hemocromatosis/diagnóstico , Hipoparatiroidismo/diagnóstico , Osteoporosis/tratamiento farmacológico , Reacción a la Transfusión , Glándulas Suprarrenales/metabolismo , Adulto , Conservadores de la Densidad Ósea/uso terapéutico , Resorción Ósea/tratamiento farmacológico , Calcio/sangre , Diabetes Mellitus/metabolismo , Hemocromatosis/etiología , Humanos , Hipogonadismo/metabolismo , Hipoparatiroidismo/metabolismo , Hipopituitarismo/metabolismo , Masculino , Osteoporosis/metabolismo , Hormona Paratiroidea/sangreRESUMEN
Nettle (Urtica dioica) is commonly sold as a herbal tea in Turkey. We report a case of gynaecomastia in a man (in which the only aetiologic factor identified was nettle tea consumption) and a case of galactorrhoea in a woman (in which the only aetiologic factor identified was also nettle tea ingestion).
Asunto(s)
Bebidas , Enfermedades del Sistema Endocrino/inducido químicamente , Estrógenos/metabolismo , Ginecomastia/inducido químicamente , Preparaciones de Plantas/efectos adversos , Urtica dioica/efectos adversos , Adulto , Enfermedades del Sistema Endocrino/diagnóstico , Enfermedades del Sistema Endocrino/metabolismo , Femenino , Galactorrea/inducido químicamente , Galactorrea/diagnóstico , Ginecomastia/diagnóstico , Humanos , MasculinoRESUMEN
The role of the human hypothalamus in the neuroendocrine response to illness has only recently begun to be explored. Extensive changes in the hypothalamus-pituitary-thyroid (HPT) axis occur within the framework of critical illness. The best-documented change in the HPT axis is a decrease in serum concentrations of the biologically active thyroid hormone triiodothyronine (T3). From studies in post-mortem human hypothalamus it appeared that low serum T3 and thyrotropin (TSH) during illness (nonthyroidal illness, NTI) are paralleled by decreased thyrotropin-releasing hormone (TRH)mRNA expression in the hypothalamic paraventricular nucleus (PVN), pointing to a major alteration in HPT axis setpoint regulation. A strong decrease in TRHmRNA expression is also present in the PVN of patients with major depression as well as in glucocorticoid-treated patients. By inference, hypercortisolism in hospitalized patients with severe depression or in critical illness may induce down-regulation of the HPT axis at the level of the hypothalamus. In order to start defining the determinants and mechanisms of these setpoint changes in various clinical conditions, it is important to note that an increasing number of hypothalamic proteins appears to be involved in central thyroid hormone metabolism. In recent studies, we have investigated the distribution and expression of thyroid hormone receptor (TR) isoforms, type 2 and type 3 deiodinase (D2 and D3), and the thyroid hormone transporter monocarboxylate transporter 8 (MCT8) in the human hypothalamus by a combination of immunocytochemistry, mRNA in situ hybridization and enzyme activity assays. Both D2 and D3 enzyme activities are detectable in the mediobasal hypothalamus. D2 immunoreactivity is prominent in glial cells of the infundibular nucleus/median eminence region and in tanycytes lining the third ventricle. Combined D2, D3, MCT8 or TR immunocytochemistry and TRHmRNA in situ hybridization indicates that D3, MCT8 and TRs are all expressed by TRH neurons in the PVN, whereas D2 is not. Taken together, these results suggest that the prohormone thyroxine (T4) is taken up in glial cells that convert T4 into the biologically active T3 via the enzyme D2; T3 is subsequently transported to TRH producing neurons in the PVN where it may bind to TRs and/or may be degraded into inactive iodothyronines by D3. This model for thyroid hormone action in the human hypothalamus awaits confirmation in future experimental studies.
Asunto(s)
Enfermedades del Sistema Endocrino/metabolismo , Retroalimentación Fisiológica/fisiología , Hipotálamo/metabolismo , Hormonas Tiroideas/metabolismo , Animales , Depresión/metabolismo , Depresión/terapia , Enfermedades del Sistema Endocrino/terapia , Humanos , Sistema Hipotálamo-Hipofisario/metabolismo , Hipotálamo/anatomía & histología , Sistema Hipófiso-Suprarrenal/metabolismoRESUMEN
Although numerous studies are available in the literature on endocrine complications in thalassaemia, little is known about this subject in developing countries. Therefore, an international multicenter study was conducted in a large series of children and adolescents with beta thalassaemia major in order to obtain more information on the prevalence of short stature and endocrine complications in different areas of the world and to elucidate the problems that must be dealt with in the future. A questionnaire was sent to 29 Centres treating a total of 3817 beta thalassaemia major patients. Thirty-six per cent of patients were over the age of 16 years. Short stature was present in 31.1% of males and 30.5% of females, and the prevalence of growth hormone deficiency was 7.9% in males and 8.8% in females. Lack of pubertal changes was the most common endocrine complication (40.5%) followed by hypoparathyroidism (6.9%), impaired glucose tolerance (6.5%), insulin-dependent diabetes mellitus (3.2%) and primary hypothyroidism (3.2%). The prevalence of endocrine complications differed among centres, particularly for growth hormone deficiency, hypoparathyroidism and hypothyroidism. Compliance to chelation therapy was poor in 51% of patients and serum liver enzymes were high in 65% of patients. Since several endocrine glands may be affected in patients with thalassaemia major, and their life expectancy is now much longer, it is important that physicians be aware of the endocrine abnormalities that may develop. Therefore, periodic evaluation of these problems should be carried out in thalassaemic patients with iron overload, particularly after the age of 11 years. In conclusion, since iron overload and liver damage seem to be the most important factors responsible for endocrine complications, adequate compliance to chelation therapy and rigid precautions against liver infections are imperative.
Asunto(s)
Estatura , Enfermedades del Sistema Endocrino/complicaciones , Talasemia beta/complicaciones , Adolescente , Adulto , Terapia por Quelación , Niño , Preescolar , Diabetes Mellitus Tipo 1/complicaciones , Enfermedades del Sistema Endocrino/metabolismo , Enfermedades del Sistema Endocrino/terapia , Femenino , Intolerancia a la Glucosa/complicaciones , Hormona de Crecimiento Humana/deficiencia , Humanos , Hipoparatiroidismo/complicaciones , Hipotiroidismo/complicaciones , Lactante , Masculino , Pubertad Tardía/complicaciones , Talasemia beta/metabolismo , Talasemia beta/terapiaRESUMEN
Analytical results obtained by ICP-MS of hair samples from a group of women from Rio de Janeiro city show that abnormal Ca and P concentrations in this compartment can be an indication of pathologies affecting the metabolism of these elements. The study was conducted initially on 900 women (outpatients, >40 years). From this group, approx. 24% showed anomalously high or low Ca concentrations in hair, in some cases correlated to anomalies of other elements. In 144 cases (16%), very high concentrations of Ca (up to 8,285 mg/kg) were measured, frequently correlated with a high concentration of P (up to 4,720 mg/kg), exceeding by far the reference intervals for this age/sex group. Follow-up studies of a few individuals from this group gave first indications that their abnormal hair compositions were related to endocrinologic pathologies affecting calcium/bone metabolism. Very low hair Ca-concentrations were observed in older women (72 cases, age >60 years) and related to senile osteoporosis. Complementary investigations of patients with recognized endocrinologic pathologies (hyperthyroidism, hyper- and hypoparathyroidism) and osteomalacia gave statistical support for the hypothesis that hair concentrations of Ca, P and various other trace elements are influenced characteristically by these diseases. In patients with hyperparathyroidism and hyperthyroidism, both elements showed significant increase in hair, whereas patients with rickets/osteomalacia had only elevated Ca concentrations, together with suspiciously high toxic levels of Cd and various other elements (Fe, Mn, Mg, Sr, Ba). Patients with hypoparathyroidism had significantly decreased Ca and P concentrations in hair. Statistical evaluation of these data by multivariant analysis (MANOVA) using a contrast matrix and by discriminant analysis showed that elemental hair anomalies can be used to diagnose correctly the above-mentioned pathologies, demonstrating the usefulness of hair analysis as a complementary tool for the detection of disturbances in calcium/bone metabolism.
Asunto(s)
Huesos/metabolismo , Calcio/deficiencia , Enfermedades del Sistema Endocrino/metabolismo , Cabello/química , Oligoelementos/análisis , Adulto , Anciano , Biomarcadores , Enfermedades del Sistema Endocrino/diagnóstico , Femenino , Humanos , Espectrometría de Masas , Persona de Mediana EdadAsunto(s)
Alopecia/veterinaria , Grasas de la Dieta/metabolismo , Enfermedades de los Perros/metabolismo , Enfermedades del Sistema Endocrino/veterinaria , Absorción , Alopecia/metabolismo , Animales , Aceite de Maíz/metabolismo , Perros , Enfermedades del Sistema Endocrino/metabolismo , Femenino , Masculino , Piel/patología , Triglicéridos/sangreRESUMEN
DNA hybridization techniques are now commonly used in studies of endocrine disease. Although solution and filter hybridization have been more widely used in endocrine studies, ISH offers many advantages to the pathologist. Individual cells can be visualized directly with the microscope to study the expression of specific gene products. ISH is somewhat similar to immunohistochemistry and can be set up rapidly in most histology laboratories, especially when nonradioactive biotinylated probes are used. The ability to combine ISH with immunochemical techniques offers to the pathologist the use of two powerful diagnostic tools simultaneously. Although DNA hybridization has only begun to have an impact in diagnostic pathology, many studies using this technique in the diagnosis of endocrine diseases are emerging. The availability of more probes, especially with nonradioactive detection systems, should accelerate the application of these techniques in diagnostic pathology. As the number of molecular probes available for hybridization studies increases, pathologists can have a major impact in this field by carefully evaluating probes that have potential diagnostic value for their specificity and sensitivity in a wide variety of normal and abnormal human tissues. Such careful and critical analyses will contribute greatly to the confidence with which these molecular probes can be used as another tool in the analysis of difficult diagnostic lesions. Molecular hybridization techniques will also contribute greatly to our knowledge of basic biology and pathophysiology in the study of abnormal gene expression in endocrine and other pathologic conditions.